Artiva Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 4.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 204.85M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/mic...